exosomes

envie a um amigo share this

Transcriptome Reprogramming of CD11b+ Bone Marrow Cells by Pancreatic Cancer Extracellular Vesicles


Joana Maia1,2, Andreia Hanada Otake1,3, Juliana Poças4,5,6, Ana Sofia Carvalho7, Hans Christian Beck8, Ana Magalhães4,5, Rune Matthiesen7, Maria Carolina Strano Moraes1 and Bruno Costa-Silva1

1-Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal

2-Graduate Program in Areas of Basic and Applied Biology, University of Porto, Porto, Portugal

Transcriptome Reprogramming of CD11b+ Bone Marrow Cells by Pancreatic Cancer Extracellular Vesicles

O cancro de pâncreas é a quarta principal causa de mortes relacionadas ao cancro no mundo, apresentando uma taxa de sobrevida de 5 anos de cerca de 6% e uma taxa de sobrevida média de cerca de 6 meses. Entre os cancros pancreáticos, o adenocarcinoma ductal pancreático (CP) é o tipo mais comum e é responsável por mais de 90% dos casos. Uma combinação de fatores leva ao mau prognóstico do CP, incluindo dificuldades na deteção da doença em estágio inicial, seu alto potencial metastático e sua resistência às terapias convencionais.

Nanotechnology in Cancer: Engineering for Oncology

Churchill College, University of Cambridge, UK

 

12 - 14 September, 2019

 

See more informations here: https://www.eacr.org/conference/nanotechnology19

Nanotechnology in Cancer: Engineering for Oncology

Churchill College, University of Cambridge, UK

 

12 - 14 September, 2019

 

See more informations here: https://www.eacr.org/conference/nanotechnology19

Exosomes facilitate targeted therapy in pancreatic cancer

Exosomes can be used as vehicles to deliver therapeutic siRNAs, which specifically target the mutant form of KRAS, to the pancreas inhibiting the action of this oncogene. About 70% of patients with pancreatic cancer harbour mutations in the gene KRAS. Exosomes carrying siRNA contain at their surface the CD47 protein, the "don't eat me" signal that allows the exosomes to bypass the clearance by the immune system.

Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells

Extracellular vesicles (EVs) are released from all cells, being not only relevant for physiological processes but also for pathological processes such as cancer. Different types of EVs, including exosomes and microvesicles, have different intracellular origin and biogenesis (exosomes have endosomal origin and smaller sizes while microvesicles have a plasma membrane origin and bigger sizes). EVs may carry different types of molecules from the donor cells, such as proteins and microRNAs.

Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis

Authors and Affiliations:

Sonia A. Melo1, 2, Hikaru Sugimoto1, 2, Joyce T. O’Connell2, Noritoshi Kato2, Alberto Villanueva3, August Vidal4, Le Qiu5, Edward Vitkin5, Lev T. Perelman5, Carlos A. Melo6, 7, Anthony Lucci8, Cristina Ivan9, George A. Calin10, Raghu Kalluri1, 2,

Glycosylation of exosomes from ovarian carcinoma cells

Authors and Affiliations:

Cristina Escrevente1, Nicolas Grammel2, Sebastian Kandzia2, Johannes Zeiser2, Erin M. Tranfield3, Harald S. Conradt2, Júlia Costa1

1.Laboratory of Glycobiology, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal

2.GlycoThera GmbH, Hannover, Germany

3.Electron Microscopy Facility, Instituto Gulbenkian de Ciência, Oeiras, Portugal

 

Abstract: